Cargando…
Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
INTRODUCTION: Apixaban has been shown to be superior to warfarin in patients with non-valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in current guidelines. There are only scarce data about its use, efficacy, and safety in unselected patients in Germany. MET...
Autores principales: | Zeymer, Uwe, Lober, Christiane, Wolf, Andreas, Richard, Frank, Schäfer, Heinrich, Taggeselle, Jens, Kabitz, Hans-Joachim, Prondzinsky, Roland, Süselbeck, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584711/ https://www.ncbi.nlm.nih.gov/pubmed/32638266 http://dx.doi.org/10.1007/s40119-020-00188-1 |
Ejemplares similares
-
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017) -
Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014) -
Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012) -
Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
por: Hersi, Ahmad S., et al.
Publicado: (2019) -
Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)